Is pstv stock strong buy today

**Plus Therapeutics (PSTV) stock is not a strong buy today**, July 1, 2025, for the following reasons: 1. **Recent Price Performance**: PSTV's stock has experienced a significant decline of -10.84% on July 1, 2025. This recent negative performance indicates a potential lack of strength in the stock. |code|Ticker|Name|Date|Closing Price|market_code| |---|---|---|---|---|---| |PSTV|PSTV.O|Plus Therapeutics|20250701|0.3101|186| 2. **Market Sentiment**: There is a mixed sentiment among analysts. While some, like H.C. Wainwright, have lowered their price target to $3.00, maintaining a Buy rating, others, such as D. Boral Capital, have maintained a Hold rating with no change in the price target at $9.00. The absence of a strong buy rating from major analysts today suggests caution. 3. **Financial Ratios**: PSTV's P/E ratio is not available, but a low P/S ratio of 0.01 could indicate that the market is not valuing the company's sales effectively. Without a P/E ratio, it's challenging to assess the stock's earnings potential. |code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code| |---|---|---|---|---|---|---|---| |OST|OST.O|Ostin Technology|20240701|-0.592504|0.21662965683406613|0.4647695514916558|186| |OST|OST.O|Ostin Technology|20240702|-0.567944|0.20765018919327582|0.445504492362468|186| |OST|OST.O|Ostin Technology|20240703|-0.595574|0.2177520902891649|0.46717768388280423|186| |OST|OST.O|Ostin Technology|20240705|-0.590969|0.2160684401065167|0.46356548529608155|186| |OST|OST.O|Ostin Technology|20240708|-0.563339|0.20596653901062764|0.44189229377574524|186| |OST|OST.O|Ostin Technology|20240709|-0.537245|0.19642585464228793|0.4214231684509832|186| |OST|OST.O|Ostin Technology|20240710|-0.543385|0.1986707215524855|0.4262394332332802|186| |OST|OST.O|Ostin Technology|20240711|-0.571014|0.2087726226483746|0.44791262475361643|186| |OST|OST.O|Ostin Technology|20240712|-0.583294|0.21326235646876976|0.45754515431821036|186| |OST|OST.O|Ostin Technology|20240715|-0.575619|0.21045627283102278|0.45152482334033917|186| 4. **Recent News**: While PSTV has announced significant developments, such as the launch of its CNSide diagnostic platform and the FDA clearance for REYOBIQ, the impact of these developments on the stock price needs time to materialize. In conclusion, given the recent price decline and the absence of a strong buy rating from analysts, PSTV stock is not a strong buy today. Investors should exercise caution and consider the potential risks before making investment decisions.